Adenosquamous cell lung cancer

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
4 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Checkpoint inhibitor (PD-1) 1 substance
Phase II: 1 Phase I (First in Human): 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • Owlstone Medical Limited Commercial
    D5-ETHYL-BETA-D-GLUCURONIDE
    2023-503574-20-00 2 countries 2023 n=100
    Ended

Phase I (First in Human)

2 trials
  • Achilles Therapeutics UK Limited Commercial
    ATL001; PEMBROLIZUMAB
    2024-513060-26-00 3 countries 2021 n=24
    Ended
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Owlstone Medical Limited Commercial 1 Phase II 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 1
New trials by year
2021
1
2023
1
2025
1
← All indication landscapes